nodes	percent_of_prediction	percent_of_DWPC	metapath
Milnacipran—Levomilnacipran—CYP3A4—bone cancer	0.0287	0.689	CrCbGaD
Milnacipran—Pethidine—CYP3A4—bone cancer	0.0129	0.311	CrCbGaD
Milnacipran—Mediastinal disorder—Cisplatin—bone cancer	0.00591	0.00617	CcSEcCtD
Milnacipran—Dry eye—Doxorubicin—bone cancer	0.00573	0.00598	CcSEcCtD
Milnacipran—Malnutrition—Cisplatin—bone cancer	0.00571	0.00596	CcSEcCtD
Milnacipran—Renal failure acute—Methotrexate—bone cancer	0.00563	0.00588	CcSEcCtD
Milnacipran—Flatulence—Cisplatin—bone cancer	0.00563	0.00587	CcSEcCtD
Milnacipran—Bladder pain—Doxorubicin—bone cancer	0.00561	0.00585	CcSEcCtD
Milnacipran—Vision blurred—Cisplatin—bone cancer	0.00538	0.00561	CcSEcCtD
Milnacipran—Tremor—Cisplatin—bone cancer	0.00535	0.00558	CcSEcCtD
Milnacipran—Renal failure acute—Epirubicin—bone cancer	0.00527	0.0055	CcSEcCtD
Milnacipran—Hot flush—Epirubicin—bone cancer	0.0052	0.00543	CcSEcCtD
Milnacipran—Menopausal symptoms—Epirubicin—bone cancer	0.00516	0.00538	CcSEcCtD
Milnacipran—Leukopenia—Cisplatin—bone cancer	0.00511	0.00533	CcSEcCtD
Milnacipran—Irritability—Methotrexate—bone cancer	0.00497	0.00518	CcSEcCtD
Milnacipran—Convulsion—Cisplatin—bone cancer	0.00495	0.00516	CcSEcCtD
Milnacipran—Hyponatraemia—Epirubicin—bone cancer	0.00489	0.0051	CcSEcCtD
Milnacipran—Renal failure acute—Doxorubicin—bone cancer	0.00488	0.00509	CcSEcCtD
Milnacipran—Anxiety—Cisplatin—bone cancer	0.00484	0.00505	CcSEcCtD
Milnacipran—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.00483	0.00504	CcSEcCtD
Milnacipran—Hot flush—Doxorubicin—bone cancer	0.00482	0.00502	CcSEcCtD
Milnacipran—Liver function test abnormal—Methotrexate—bone cancer	0.0048	0.00501	CcSEcCtD
Milnacipran—Migraine—Epirubicin—bone cancer	0.00479	0.005	CcSEcCtD
Milnacipran—Menopausal symptoms—Doxorubicin—bone cancer	0.00477	0.00498	CcSEcCtD
Milnacipran—Breast disorder—Methotrexate—bone cancer	0.0047	0.00491	CcSEcCtD
Milnacipran—Infection—Cisplatin—bone cancer	0.00463	0.00483	CcSEcCtD
Milnacipran—Nervous system disorder—Cisplatin—bone cancer	0.00457	0.00477	CcSEcCtD
Milnacipran—Thrombocytopenia—Cisplatin—bone cancer	0.00456	0.00476	CcSEcCtD
Milnacipran—Tachycardia—Cisplatin—bone cancer	0.00455	0.00474	CcSEcCtD
Milnacipran—Skin disorder—Cisplatin—bone cancer	0.00453	0.00472	CcSEcCtD
Milnacipran—Hyponatraemia—Doxorubicin—bone cancer	0.00452	0.00472	CcSEcCtD
Milnacipran—Hyperhidrosis—Cisplatin—bone cancer	0.0045	0.0047	CcSEcCtD
Milnacipran—Liver function test abnormal—Epirubicin—bone cancer	0.00449	0.00469	CcSEcCtD
Milnacipran—Dry skin—Epirubicin—bone cancer	0.00446	0.00466	CcSEcCtD
Milnacipran—Anorexia—Cisplatin—bone cancer	0.00444	0.00463	CcSEcCtD
Milnacipran—Migraine—Doxorubicin—bone cancer	0.00443	0.00463	CcSEcCtD
Milnacipran—Breast disorder—Epirubicin—bone cancer	0.0044	0.00459	CcSEcCtD
Milnacipran—Hypotension—Cisplatin—bone cancer	0.00435	0.00454	CcSEcCtD
Milnacipran—Abdominal distension—Epirubicin—bone cancer	0.00424	0.00442	CcSEcCtD
Milnacipran—Dysuria—Methotrexate—bone cancer	0.0042	0.00439	CcSEcCtD
Milnacipran—Neutropenia—Methotrexate—bone cancer	0.0042	0.00439	CcSEcCtD
Milnacipran—Paraesthesia—Cisplatin—bone cancer	0.00418	0.00437	CcSEcCtD
Milnacipran—Upper respiratory tract infection—Methotrexate—bone cancer	0.00418	0.00436	CcSEcCtD
Milnacipran—Liver function test abnormal—Doxorubicin—bone cancer	0.00416	0.00434	CcSEcCtD
Milnacipran—Dyspnoea—Cisplatin—bone cancer	0.00415	0.00433	CcSEcCtD
Milnacipran—Erectile dysfunction—Methotrexate—bone cancer	0.00414	0.00432	CcSEcCtD
Milnacipran—Dry skin—Doxorubicin—bone cancer	0.00413	0.00431	CcSEcCtD
Milnacipran—Angina pectoris—Epirubicin—bone cancer	0.0041	0.00428	CcSEcCtD
Milnacipran—Breast disorder—Doxorubicin—bone cancer	0.00407	0.00425	CcSEcCtD
Milnacipran—Decreased appetite—Cisplatin—bone cancer	0.00405	0.00423	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Cisplatin—bone cancer	0.00402	0.0042	CcSEcCtD
Milnacipran—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.00397	0.00415	CcSEcCtD
Milnacipran—Dysuria—Epirubicin—bone cancer	0.00393	0.00411	CcSEcCtD
Milnacipran—Neutropenia—Epirubicin—bone cancer	0.00393	0.00411	CcSEcCtD
Milnacipran—Abdominal distension—Doxorubicin—bone cancer	0.00392	0.00409	CcSEcCtD
Milnacipran—Upper respiratory tract infection—Epirubicin—bone cancer	0.00391	0.00408	CcSEcCtD
Milnacipran—Pollakiuria—Epirubicin—bone cancer	0.00389	0.00406	CcSEcCtD
Milnacipran—Haematuria—Methotrexate—bone cancer	0.00382	0.00399	CcSEcCtD
Milnacipran—Weight decreased—Epirubicin—bone cancer	0.00381	0.00397	CcSEcCtD
Milnacipran—Angina pectoris—Doxorubicin—bone cancer	0.00379	0.00396	CcSEcCtD
Milnacipran—Hepatobiliary disease—Methotrexate—bone cancer	0.00379	0.00396	CcSEcCtD
Milnacipran—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.00372	0.00388	CcSEcCtD
Milnacipran—Body temperature increased—Cisplatin—bone cancer	0.00368	0.00384	CcSEcCtD
Milnacipran—Urinary tract infection—Epirubicin—bone cancer	0.00365	0.00381	CcSEcCtD
Milnacipran—Dysuria—Doxorubicin—bone cancer	0.00364	0.0038	CcSEcCtD
Milnacipran—Neutropenia—Doxorubicin—bone cancer	0.00364	0.0038	CcSEcCtD
Milnacipran—Upper respiratory tract infection—Doxorubicin—bone cancer	0.00362	0.00378	CcSEcCtD
Milnacipran—Hepatitis—Methotrexate—bone cancer	0.0036	0.00376	CcSEcCtD
Milnacipran—Pollakiuria—Doxorubicin—bone cancer	0.0036	0.00375	CcSEcCtD
Milnacipran—Haematuria—Epirubicin—bone cancer	0.00358	0.00373	CcSEcCtD
Milnacipran—Urinary tract disorder—Methotrexate—bone cancer	0.00355	0.00371	CcSEcCtD
Milnacipran—Hepatobiliary disease—Epirubicin—bone cancer	0.00355	0.0037	CcSEcCtD
Milnacipran—Urethral disorder—Methotrexate—bone cancer	0.00353	0.00368	CcSEcCtD
Milnacipran—Weight decreased—Doxorubicin—bone cancer	0.00352	0.00368	CcSEcCtD
Milnacipran—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.00344	0.00359	CcSEcCtD
Milnacipran—Hypersensitivity—Cisplatin—bone cancer	0.00343	0.00358	CcSEcCtD
Milnacipran—Erythema multiforme—Methotrexate—bone cancer	0.0034	0.00355	CcSEcCtD
Milnacipran—Urinary tract infection—Doxorubicin—bone cancer	0.00337	0.00352	CcSEcCtD
Milnacipran—Hepatitis—Epirubicin—bone cancer	0.00337	0.00351	CcSEcCtD
Milnacipran—Eye disorder—Methotrexate—bone cancer	0.00336	0.00351	CcSEcCtD
Milnacipran—Hypoaesthesia—Epirubicin—bone cancer	0.00335	0.0035	CcSEcCtD
Milnacipran—Asthenia—Cisplatin—bone cancer	0.00334	0.00349	CcSEcCtD
Milnacipran—Cardiac disorder—Methotrexate—bone cancer	0.00334	0.00349	CcSEcCtD
Milnacipran—Urinary tract disorder—Epirubicin—bone cancer	0.00333	0.00347	CcSEcCtD
Milnacipran—Oedema peripheral—Epirubicin—bone cancer	0.00332	0.00346	CcSEcCtD
Milnacipran—Haematuria—Doxorubicin—bone cancer	0.00331	0.00345	CcSEcCtD
Milnacipran—Connective tissue disorder—Epirubicin—bone cancer	0.00331	0.00345	CcSEcCtD
Milnacipran—Urethral disorder—Epirubicin—bone cancer	0.0033	0.00344	CcSEcCtD
Milnacipran—Hepatobiliary disease—Doxorubicin—bone cancer	0.00328	0.00343	CcSEcCtD
Milnacipran—Angiopathy—Methotrexate—bone cancer	0.00327	0.00341	CcSEcCtD
Milnacipran—Mediastinal disorder—Methotrexate—bone cancer	0.00324	0.00338	CcSEcCtD
Milnacipran—Chills—Methotrexate—bone cancer	0.00323	0.00337	CcSEcCtD
Milnacipran—Diarrhoea—Cisplatin—bone cancer	0.00319	0.00333	CcSEcCtD
Milnacipran—Erythema multiforme—Epirubicin—bone cancer	0.00318	0.00332	CcSEcCtD
Milnacipran—Mental disorder—Methotrexate—bone cancer	0.00315	0.00329	CcSEcCtD
Milnacipran—Eye disorder—Epirubicin—bone cancer	0.00315	0.00328	CcSEcCtD
Milnacipran—Malnutrition—Methotrexate—bone cancer	0.00313	0.00327	CcSEcCtD
Milnacipran—Cardiac disorder—Epirubicin—bone cancer	0.00313	0.00326	CcSEcCtD
Milnacipran—Flushing—Epirubicin—bone cancer	0.00313	0.00326	CcSEcCtD
Milnacipran—Hepatitis—Doxorubicin—bone cancer	0.00312	0.00325	CcSEcCtD
Milnacipran—Hypoaesthesia—Doxorubicin—bone cancer	0.0031	0.00324	CcSEcCtD
Milnacipran—Urinary tract disorder—Doxorubicin—bone cancer	0.00308	0.00321	CcSEcCtD
Milnacipran—Oedema peripheral—Doxorubicin—bone cancer	0.00307	0.0032	CcSEcCtD
Milnacipran—Dysgeusia—Methotrexate—bone cancer	0.00307	0.0032	CcSEcCtD
Milnacipran—Connective tissue disorder—Doxorubicin—bone cancer	0.00306	0.0032	CcSEcCtD
Milnacipran—Angiopathy—Epirubicin—bone cancer	0.00306	0.00319	CcSEcCtD
Milnacipran—Urethral disorder—Doxorubicin—bone cancer	0.00305	0.00319	CcSEcCtD
Milnacipran—Mediastinal disorder—Epirubicin—bone cancer	0.00304	0.00317	CcSEcCtD
Milnacipran—Chills—Epirubicin—bone cancer	0.00302	0.00315	CcSEcCtD
Milnacipran—Vomiting—Cisplatin—bone cancer	0.00296	0.00309	CcSEcCtD
Milnacipran—Vision blurred—Methotrexate—bone cancer	0.00295	0.00308	CcSEcCtD
Milnacipran—Mental disorder—Epirubicin—bone cancer	0.00295	0.00308	CcSEcCtD
Milnacipran—Erythema multiforme—Doxorubicin—bone cancer	0.00295	0.00307	CcSEcCtD
Milnacipran—Rash—Cisplatin—bone cancer	0.00294	0.00307	CcSEcCtD
Milnacipran—Dermatitis—Cisplatin—bone cancer	0.00294	0.00306	CcSEcCtD
Milnacipran—Malnutrition—Epirubicin—bone cancer	0.00293	0.00306	CcSEcCtD
Milnacipran—Eye disorder—Doxorubicin—bone cancer	0.00291	0.00304	CcSEcCtD
Milnacipran—Cardiac disorder—Doxorubicin—bone cancer	0.00289	0.00302	CcSEcCtD
Milnacipran—Flushing—Doxorubicin—bone cancer	0.00289	0.00302	CcSEcCtD
Milnacipran—Flatulence—Epirubicin—bone cancer	0.00289	0.00301	CcSEcCtD
Milnacipran—Tension—Epirubicin—bone cancer	0.00288	0.003	CcSEcCtD
Milnacipran—Dysgeusia—Epirubicin—bone cancer	0.00287	0.003	CcSEcCtD
Milnacipran—Angiopathy—Doxorubicin—bone cancer	0.00283	0.00295	CcSEcCtD
Milnacipran—Mediastinal disorder—Doxorubicin—bone cancer	0.00281	0.00293	CcSEcCtD
Milnacipran—Leukopenia—Methotrexate—bone cancer	0.0028	0.00293	CcSEcCtD
Milnacipran—Chills—Doxorubicin—bone cancer	0.0028	0.00292	CcSEcCtD
Milnacipran—Nausea—Cisplatin—bone cancer	0.00277	0.00289	CcSEcCtD
Milnacipran—Vision blurred—Epirubicin—bone cancer	0.00276	0.00288	CcSEcCtD
Milnacipran—Mental disorder—Doxorubicin—bone cancer	0.00273	0.00285	CcSEcCtD
Milnacipran—Convulsion—Methotrexate—bone cancer	0.00271	0.00283	CcSEcCtD
Milnacipran—Malnutrition—Doxorubicin—bone cancer	0.00271	0.00283	CcSEcCtD
Milnacipran—Agitation—Epirubicin—bone cancer	0.00269	0.00281	CcSEcCtD
Milnacipran—Flatulence—Doxorubicin—bone cancer	0.00267	0.00279	CcSEcCtD
Milnacipran—Chest pain—Methotrexate—bone cancer	0.00267	0.00278	CcSEcCtD
Milnacipran—Tension—Doxorubicin—bone cancer	0.00266	0.00278	CcSEcCtD
Milnacipran—Dysgeusia—Doxorubicin—bone cancer	0.00266	0.00277	CcSEcCtD
Milnacipran—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.00265	0.00276	CcSEcCtD
Milnacipran—Syncope—Epirubicin—bone cancer	0.00263	0.00274	CcSEcCtD
Milnacipran—Leukopenia—Epirubicin—bone cancer	0.00262	0.00274	CcSEcCtD
Milnacipran—Palpitations—Epirubicin—bone cancer	0.00259	0.0027	CcSEcCtD
Milnacipran—Loss of consciousness—Epirubicin—bone cancer	0.00258	0.00269	CcSEcCtD
Milnacipran—Vision blurred—Doxorubicin—bone cancer	0.00256	0.00267	CcSEcCtD
Milnacipran—Convulsion—Epirubicin—bone cancer	0.00254	0.00265	CcSEcCtD
Milnacipran—Infection—Methotrexate—bone cancer	0.00254	0.00265	CcSEcCtD
Milnacipran—Hypertension—Epirubicin—bone cancer	0.00253	0.00264	CcSEcCtD
Milnacipran—Nervous system disorder—Methotrexate—bone cancer	0.00251	0.00262	CcSEcCtD
Milnacipran—Thrombocytopenia—Methotrexate—bone cancer	0.0025	0.00261	CcSEcCtD
Milnacipran—Chest pain—Epirubicin—bone cancer	0.0025	0.0026	CcSEcCtD
Milnacipran—Agitation—Doxorubicin—bone cancer	0.00249	0.0026	CcSEcCtD
Milnacipran—Anxiety—Epirubicin—bone cancer	0.00249	0.0026	CcSEcCtD
Milnacipran—Skin disorder—Methotrexate—bone cancer	0.00248	0.00259	CcSEcCtD
Milnacipran—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.00248	0.00259	CcSEcCtD
Milnacipran—Hyperhidrosis—Methotrexate—bone cancer	0.00247	0.00258	CcSEcCtD
Milnacipran—Dry mouth—Epirubicin—bone cancer	0.00244	0.00255	CcSEcCtD
Milnacipran—Anorexia—Methotrexate—bone cancer	0.00244	0.00254	CcSEcCtD
Milnacipran—Syncope—Doxorubicin—bone cancer	0.00243	0.00254	CcSEcCtD
Milnacipran—Leukopenia—Doxorubicin—bone cancer	0.00243	0.00253	CcSEcCtD
Milnacipran—Palpitations—Doxorubicin—bone cancer	0.0024	0.0025	CcSEcCtD
Milnacipran—Hypotension—Methotrexate—bone cancer	0.00239	0.00249	CcSEcCtD
Milnacipran—Loss of consciousness—Doxorubicin—bone cancer	0.00238	0.00249	CcSEcCtD
Milnacipran—Infection—Epirubicin—bone cancer	0.00238	0.00248	CcSEcCtD
Milnacipran—Shock—Epirubicin—bone cancer	0.00235	0.00246	CcSEcCtD
Milnacipran—Convulsion—Doxorubicin—bone cancer	0.00235	0.00245	CcSEcCtD
Milnacipran—Nervous system disorder—Epirubicin—bone cancer	0.00235	0.00245	CcSEcCtD
Milnacipran—Thrombocytopenia—Epirubicin—bone cancer	0.00234	0.00244	CcSEcCtD
Milnacipran—Hypertension—Doxorubicin—bone cancer	0.00234	0.00244	CcSEcCtD
Milnacipran—Tachycardia—Epirubicin—bone cancer	0.00234	0.00244	CcSEcCtD
Milnacipran—Skin disorder—Epirubicin—bone cancer	0.00232	0.00243	CcSEcCtD
Milnacipran—Hyperhidrosis—Epirubicin—bone cancer	0.00231	0.00241	CcSEcCtD
Milnacipran—Insomnia—Methotrexate—bone cancer	0.00231	0.00241	CcSEcCtD
Milnacipran—Chest pain—Doxorubicin—bone cancer	0.00231	0.00241	CcSEcCtD
Milnacipran—Anxiety—Doxorubicin—bone cancer	0.0023	0.0024	CcSEcCtD
Milnacipran—Paraesthesia—Methotrexate—bone cancer	0.0023	0.0024	CcSEcCtD
Milnacipran—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.00229	0.00239	CcSEcCtD
Milnacipran—Anorexia—Epirubicin—bone cancer	0.00228	0.00238	CcSEcCtD
Milnacipran—Dyspnoea—Methotrexate—bone cancer	0.00228	0.00238	CcSEcCtD
Milnacipran—Somnolence—Methotrexate—bone cancer	0.00227	0.00237	CcSEcCtD
Milnacipran—Dry mouth—Doxorubicin—bone cancer	0.00226	0.00236	CcSEcCtD
Milnacipran—Dyspepsia—Methotrexate—bone cancer	0.00225	0.00235	CcSEcCtD
Milnacipran—Hypotension—Epirubicin—bone cancer	0.00224	0.00233	CcSEcCtD
Milnacipran—Decreased appetite—Methotrexate—bone cancer	0.00222	0.00232	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Methotrexate—bone cancer	0.00221	0.0023	CcSEcCtD
Milnacipran—Fatigue—Methotrexate—bone cancer	0.0022	0.0023	CcSEcCtD
Milnacipran—Infection—Doxorubicin—bone cancer	0.0022	0.00229	CcSEcCtD
Milnacipran—Shock—Doxorubicin—bone cancer	0.00218	0.00227	CcSEcCtD
Milnacipran—Nervous system disorder—Doxorubicin—bone cancer	0.00217	0.00227	CcSEcCtD
Milnacipran—Thrombocytopenia—Doxorubicin—bone cancer	0.00217	0.00226	CcSEcCtD
Milnacipran—Insomnia—Epirubicin—bone cancer	0.00216	0.00226	CcSEcCtD
Milnacipran—Tachycardia—Doxorubicin—bone cancer	0.00216	0.00225	CcSEcCtD
Milnacipran—Skin disorder—Doxorubicin—bone cancer	0.00215	0.00224	CcSEcCtD
Milnacipran—Paraesthesia—Epirubicin—bone cancer	0.00215	0.00224	CcSEcCtD
Milnacipran—Hyperhidrosis—Doxorubicin—bone cancer	0.00214	0.00223	CcSEcCtD
Milnacipran—Dyspnoea—Epirubicin—bone cancer	0.00213	0.00223	CcSEcCtD
Milnacipran—Somnolence—Epirubicin—bone cancer	0.00213	0.00222	CcSEcCtD
Milnacipran—Anorexia—Doxorubicin—bone cancer	0.00211	0.0022	CcSEcCtD
Milnacipran—Dyspepsia—Epirubicin—bone cancer	0.00211	0.0022	CcSEcCtD
Milnacipran—Gastrointestinal pain—Methotrexate—bone cancer	0.00209	0.00218	CcSEcCtD
Milnacipran—Decreased appetite—Epirubicin—bone cancer	0.00208	0.00217	CcSEcCtD
Milnacipran—Hypotension—Doxorubicin—bone cancer	0.00207	0.00216	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Epirubicin—bone cancer	0.00207	0.00216	CcSEcCtD
Milnacipran—Fatigue—Epirubicin—bone cancer	0.00206	0.00215	CcSEcCtD
Milnacipran—Constipation—Epirubicin—bone cancer	0.00205	0.00213	CcSEcCtD
Milnacipran—Urticaria—Methotrexate—bone cancer	0.00203	0.00212	CcSEcCtD
Milnacipran—Abdominal pain—Methotrexate—bone cancer	0.00202	0.00211	CcSEcCtD
Milnacipran—Body temperature increased—Methotrexate—bone cancer	0.00202	0.00211	CcSEcCtD
Milnacipran—Insomnia—Doxorubicin—bone cancer	0.002	0.00209	CcSEcCtD
Milnacipran—Paraesthesia—Doxorubicin—bone cancer	0.00199	0.00207	CcSEcCtD
Milnacipran—Dyspnoea—Doxorubicin—bone cancer	0.00197	0.00206	CcSEcCtD
Milnacipran—Somnolence—Doxorubicin—bone cancer	0.00197	0.00205	CcSEcCtD
Milnacipran—Gastrointestinal pain—Epirubicin—bone cancer	0.00196	0.00204	CcSEcCtD
Milnacipran—Dyspepsia—Doxorubicin—bone cancer	0.00195	0.00203	CcSEcCtD
Milnacipran—Decreased appetite—Doxorubicin—bone cancer	0.00192	0.00201	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Doxorubicin—bone cancer	0.00191	0.00199	CcSEcCtD
Milnacipran—Fatigue—Doxorubicin—bone cancer	0.00191	0.00199	CcSEcCtD
Milnacipran—Urticaria—Epirubicin—bone cancer	0.0019	0.00198	CcSEcCtD
Milnacipran—Constipation—Doxorubicin—bone cancer	0.00189	0.00198	CcSEcCtD
Milnacipran—Abdominal pain—Epirubicin—bone cancer	0.00189	0.00197	CcSEcCtD
Milnacipran—Body temperature increased—Epirubicin—bone cancer	0.00189	0.00197	CcSEcCtD
Milnacipran—Hypersensitivity—Methotrexate—bone cancer	0.00188	0.00197	CcSEcCtD
Milnacipran—Asthenia—Methotrexate—bone cancer	0.00183	0.00191	CcSEcCtD
Milnacipran—Gastrointestinal pain—Doxorubicin—bone cancer	0.00181	0.00189	CcSEcCtD
Milnacipran—Pruritus—Methotrexate—bone cancer	0.00181	0.00189	CcSEcCtD
Milnacipran—Hypersensitivity—Epirubicin—bone cancer	0.00176	0.00184	CcSEcCtD
Milnacipran—Urticaria—Doxorubicin—bone cancer	0.00176	0.00184	CcSEcCtD
Milnacipran—Abdominal pain—Doxorubicin—bone cancer	0.00175	0.00183	CcSEcCtD
Milnacipran—Body temperature increased—Doxorubicin—bone cancer	0.00175	0.00183	CcSEcCtD
Milnacipran—Diarrhoea—Methotrexate—bone cancer	0.00175	0.00183	CcSEcCtD
Milnacipran—Asthenia—Epirubicin—bone cancer	0.00172	0.00179	CcSEcCtD
Milnacipran—Pruritus—Epirubicin—bone cancer	0.00169	0.00177	CcSEcCtD
Milnacipran—Dizziness—Methotrexate—bone cancer	0.00169	0.00176	CcSEcCtD
Milnacipran—Diarrhoea—Epirubicin—bone cancer	0.00164	0.00171	CcSEcCtD
Milnacipran—Hypersensitivity—Doxorubicin—bone cancer	0.00163	0.0017	CcSEcCtD
Milnacipran—Vomiting—Methotrexate—bone cancer	0.00163	0.0017	CcSEcCtD
Milnacipran—Rash—Methotrexate—bone cancer	0.00161	0.00168	CcSEcCtD
Milnacipran—Dermatitis—Methotrexate—bone cancer	0.00161	0.00168	CcSEcCtD
Milnacipran—Headache—Methotrexate—bone cancer	0.0016	0.00167	CcSEcCtD
Milnacipran—Asthenia—Doxorubicin—bone cancer	0.00159	0.00166	CcSEcCtD
Milnacipran—Dizziness—Epirubicin—bone cancer	0.00158	0.00165	CcSEcCtD
Milnacipran—Pruritus—Doxorubicin—bone cancer	0.00157	0.00163	CcSEcCtD
Milnacipran—Vomiting—Epirubicin—bone cancer	0.00152	0.00159	CcSEcCtD
Milnacipran—Nausea—Methotrexate—bone cancer	0.00152	0.00158	CcSEcCtD
Milnacipran—Diarrhoea—Doxorubicin—bone cancer	0.00151	0.00158	CcSEcCtD
Milnacipran—Rash—Epirubicin—bone cancer	0.00151	0.00157	CcSEcCtD
Milnacipran—Dermatitis—Epirubicin—bone cancer	0.00151	0.00157	CcSEcCtD
Milnacipran—Headache—Epirubicin—bone cancer	0.0015	0.00156	CcSEcCtD
Milnacipran—Dizziness—Doxorubicin—bone cancer	0.00146	0.00153	CcSEcCtD
Milnacipran—Nausea—Epirubicin—bone cancer	0.00142	0.00148	CcSEcCtD
Milnacipran—Vomiting—Doxorubicin—bone cancer	0.00141	0.00147	CcSEcCtD
Milnacipran—Rash—Doxorubicin—bone cancer	0.0014	0.00146	CcSEcCtD
Milnacipran—Dermatitis—Doxorubicin—bone cancer	0.00139	0.00146	CcSEcCtD
Milnacipran—Headache—Doxorubicin—bone cancer	0.00139	0.00145	CcSEcCtD
Milnacipran—Nausea—Doxorubicin—bone cancer	0.00132	0.00137	CcSEcCtD
